Drugs / HER2Bi-Armed Activated T Cells
HER2Bi-Armed Activated T Cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02470559 | Jun 2015 → Feb 2017 | fallopian tube carcinoma, malignant ovarian serous tumor, ovarian carcinoma, ovarian clear cell cancer +1 | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03406858 | Jun 2018 → Jan 2021 | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01147016 | Jul 2010 → Jul 2017 | breast cancer | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01022138 | Mar 2010 → Nov 2015 | breast cancer | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2Bi-Armed Activated T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406858 ↗ |
| Known as | aATC | “Her2Bi-armed activated T cells (ATC) (aATC) given twice per week for 4 weeks” NCT01147016 ↗ |
| Known as | ATC | “Her2Bi-armed activated T cells (ATC) (aATC) given twice per week for 4 weeks” NCT01147016 ↗ |
| Action | Deplete | “Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body.” NCT01022138 ↗ |
| Modality | Cell therapy | “Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body.” NCT01022138 ↗ |
| Route | Intravenous | “the first infusion of anti-CD3 x anti-HER2/neu bispecific antibody-armed activated T-cells (ATC) IV over 30-60 minutes once a week for 3 weeks” NCT01022138 ↗ |